Southpoint Capital Advisors’s Tango Therapeutics TNGX Stock Holding History

Southpoint Capital Advisors’s Portfolio TNGX Stock Details TNGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-5,000,000	Closed	-$38.5M	–	53
2024 Q3	$38.5M	Sell	5,000,000 -276,699	-5%	-$2.64M	0.91%	34
2024 Q2	$45.3M	Hold	5,276,699	–	–	1.13%	33
2024 Q1	$41.9M	Hold	5,276,699	–	–	0.83%	39
2023 Q4	$52.2M	Hold	5,276,699	–	–	1.12%	26
2023 Q3	$59.4M	Buy	5,276,699 +776,699	+17%	+$4.74M	1.33%	27
2023 Q2	$14.9M	Hold	4,500,000	–	–	0.32%	40
2023 Q1	$17.8M	Hold	4,500,000	–	–	0.4%	46
2022 Q4	$32.6M	Hold	4,500,000	–	–	0.84%	31
2022 Q3	$16.3M	Hold	4,500,000	–	–	0.44%	35
2022 Q2	$20.4M	Buy	4,500,000 +694,071	+18%	+$4.2M	0.58%	33
2022 Q1	$28.8M	Buy	3,805,929 +805,929	+27%	+$6.98M	0.56%	38
2021 Q4	$32.8M	Hold	3,000,000	–	–	0.63%	36
2021 Q3	$38.8M	Buy	3,000,000 +1,000,000	+50%	+$12M	0.83%	32
2021 Q2	$22.8M	Buy	2,000,000 +1,150,000	+135%	+$12.9M	0.39%	45
2021 Q1	$9.45M	Hold	850,000	–	–	0.15%	53
2020 Q4	$9.72M	Hold	850,000	–	–	0.17%	54
2020 Q3	$8.81M	Buy	+850,000	New	+$8.68M	0.2%	60

Other funds holding TNGX

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Southpoint Capital Advisors's TNGX Position: Q4 2024 in Review

Southpoint Capital Advisors sold out of Tango Therapeutics (TNGX) in Q4 2024, closing a stake of 5,000,000 shares — an estimated $38.5M sold.

Southpoint Capital Advisors first reported a position in TNGX in Q3 2020 and held it in 17 quarters. The position peaked at $59.4M in Q3 2023. 137 funds tracked by Wall St. Rank hold TNGX as of Q4 2024.

Southpoint Capital Advisors reported no remaining Tango Therapeutics position as of Q4 2024 after selling out during the quarter.
Southpoint Capital Advisors sold 5,000,000 Tango Therapeutics shares in Q4 2024, an estimated $38.5M.
Southpoint Capital Advisors first reported a position in Tango Therapeutics in Q3 2020 and held it in 17 quarters.
Southpoint Capital Advisors's Tango Therapeutics position peaked at $59.4M in Q3 2023.
137 funds tracked by Wall St. Rank held Tango Therapeutics as of Q4 2024.

Based on Southpoint Capital Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.